Risk factors for peripheral arterial disease in type 2 diabetes mellitus patients: A systematic review and meta-analysis [0.03%]
2型糖尿病外周动脉疾病的风险因素：系统评价和荟萃分析
Martha Rosana,Em Yunir,Ninik Saragih et al.
Martha Rosana et al.
Background: Peripheral arterial disease (PAD) is a complication of type 2 diabetes mellitus (T2DM). No systematic review has been conducted regarding the risk factors of PAD in T2DM populations. ...
Corneal confocal microscopy identifies early and definite diabetic cardiac autonomic neuropathy [0.03%]
角膜共焦显微镜识别早期明确的糖尿病自主神经病变
Shazli Azmi,Maryam Ferdousi,Alise Kalteniece et al.
Shazli Azmi et al.
Objective: Advanced cardiac autonomic neuropathy (CAN) is associated with increased mortality in people with diabetes. Early identification and reduction of risk factors can limit the progression of CAN. However, the diag...
Impact of diabetes on long-term mortality following major lower limb amputation: A population-based cohort study in Wales [0.03%]
糖尿病对下肢重大截肢术后长期死亡率影响的队列研究——基于威尔士人口数据库的一项研究
Jennifer Hayes,James M Rafferty,Wai-Yee Cheung et al.
Jennifer Hayes et al.
Background: Major lower limb amputation is associated with high morbidity and mortality, particularly among patients with diabetes. Previous studies suggest variable mortality rates, but none have investigated the impact ...
The automated correction index (ACI), a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapy [0.03%]
一种新颖的基于报告衍生指标自动校正指数（ACI）与1型糖尿病患者在接受先进混合闭环治疗下的血糖控制和变化相关的研究
Andrea Tumminia,Gaetano Maria Santoro,Vittorio Oteri et al.
Andrea Tumminia et al.
Objective: This study aimed to correlate the parameters of advanced hybrid closed loop (AHCL) function to the glycometabolic outcomes in a cohort of patients with type 1 diabetes (T1D) using different AHCL systems. ...
1. Detection of diabetes and intermediate hyperglycaemia, and prevention of type 2 diabetes [0.03%]
糖尿病和前期高血糖的检测以及2型糖尿病的预防
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes [0.03%]
第7部分：2型糖尿病患者的代谢紊乱相关肝脂肪变性疾病（MAFLD）管理建议
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
4. BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN OPTIONS FOR TYPE 2 DIABETES [0.03%]
4.降糖疗法-2型糖尿病的胰岛素品种选择
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
3. BLOOD GLUCOSE-LOWERING THERAPIES - NON-INSULIN OPTIONS FOR TYPE 2 DIABETES [0.03%]
3. 降血糖治疗措施——用于2型糖尿病的非胰岛素药物选项
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri
Stephen Colagiuri,Antonio Ceriello;IDF Technical Working Group
Stephen Colagiuri